Back

Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: How to treat HFpEF in 2022 and beyond Comorbidities ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

3 More presentations in this session

Presentation thumbnail
Treating HFpEF: State of the art 2022
Professor S. Solomon (Boston, US)
Slides Video
Presentation thumbnail
Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled
Professor J. Butler (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial
Doctor K. Bunting (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
How to treat HFpEF in 2022 and beyond
Video

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Therapeutic implications of the cardio-renal-metabolic multimorbidity
thumbnail
Congress Presentation
Obesity and inactivity cluster is the strongest predictor of incident heart failure in a population-based study
thumbnail
Congress Presentation
Defining patterns of comorbidity accrual before and after the diagnosis of heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources